Frontlight ResearchEarly access
CompletedPhase 3
Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis
Key facts
- Who runs it
- Cairo University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 80 people enrolled
- Started
- 12 Mar 2023
- Ended
- 29 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Nifuroxazide
- Lactulose
- Rifaximin 550Mg Tab
- Record updated
- 2 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Patients suffering from liver cirrhosis aging above 18 years who will be admitted to hospital with neuropsychiatric condition suggestive of hepatic encephalopathy (grade II or III) confirmed by their known previous hepatic disease by history, clinical examination and laboratory investigations in the form of hyperammonemia with Model for End-Stage Liver Disease (MELD) score ≤ 25 and patients are able to swallow
Who cannot take part
- Patients with previous intake of nifuroxazide and rifaximin within the last month
- Alcohol consumption within prior 4 weeks
- Degenerative central nervous system (CNS) disease
- Any significant psychiatric illness
- Presence of underlying renal impairment (serum creatinine ≥ 2 mg/dL)
- Anemia with hemoglobin level < 7 g/dL
- Patients with neurological or communication problems
- Non-hepatic metabolic encephalopathy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a pilot study designed to evaluate the efficacy and safety of nifuroxazide in the treatment of hepatic encephalopathy in patients with grade II-III hepatic encephalopathy
The 2 groups in the trial
- lactulose plus Rifaximin plus nifuroxazideTreatment being tested
Nifuroxazide dosing : 800 mg daily in 4 divided doses for 7 days Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day. Rifaximin: 550 mg twice daily
Treatment: Nifuroxazide, Lactulose, and Rifaximin 550Mg Tab
- Lactulose plus RifaximinExisting treatment, for comparison
Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day. Rifaximin: 550 mg twice daily
Treatment: Lactulose and Rifaximin 550Mg Tab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 2 September 2025